File(s) not publicly available
Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study
journal contribution
posted on 2023-06-08, 10:49 authored by A Mocroft, A N Philips, J Gatell, M Fisher, N Clumeck, M Losso, A Lazzarin, G Fatkenheur, J D Lundgren, B LedergerberBackground Combination antiretroviral therapy (cART) has been shown to reduce mortality and morbidity in patients with HIV. As viral replication falls, the CD4 count increases, but whether the CD4 count returns to the level seen in HIV-negative people is unknown. We aimed to assess whether the CD4 count for patients with maximum virological suppression (viral load <50 copies per mL) continues to increase with long-term cART to reach levels seen in HIV-negative populations. Methods We compared increases in CD4 counts in 1835 antiretroviral-naive patients who started cART from EuroSIDA, a pan-European observational cohort study. Rate of increase in CD4 count (per year) occurring between pairs of consecutive viral loads below 50 copies per mL was estimated using generalised linear models, accounting for multiple measurements for individual patients. Findings The median CD4 count at starting cART was 204 cells per µL (IQR 85–330). The greatest mean yearly increase in CD4 count of 100 cells per µL was seen in the year after starting cART. Significant, but lower, yearly increases in CD4 count, around 50 cells per µL, were seen even at 5 years after starting cART in patients whose current CD4 count was less than 500 cells per µL. The only groups without significant increases in CD4 count were those where cART had been taken for more than 5 years with a current CD4 count of more than 500 cells per µL, (current mean CD4 count 774 cells per µL; 95% CI 764–783). Patients starting cART with low CD4 counts (<200 cells per µL) had significant rises in CD4 counts even after 5 years of cART. Interpretation Normalisation of CD4 counts in HIV-infected patients for all infected individuals might be achievable if viral suppression with cART can be maintained for a sufficiently long period of time.
History
Publication status
- Published
Journal
LancetISSN
0140-6736Publisher
ElsevierExternal DOI
Issue
9585Volume
370Page range
407-413Department affiliated with
- Clinical and Experimental Medicine Publications
Full text available
- No
Peer reviewed?
- Yes
Legacy Posted Date
2012-02-21Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC